Acid Suppression Therapy for Pediatric GERD

First‑Line Pharmacologic Therapy

Proton pump inhibitors (PPIs) are the recommended first‑line agents for children with GERD, with omeprazole, lansoprazole, and esomeprazole approved by the FDA for pediatric use. The dosing ranges are 0.7–3.3 mg/kg/day for omeprazole and esomeprazole, and 0.7–3 mg/kg/day for lansoprazole. Ages approved: omeprazole 2–16 yr, lansoprazole 1–17 yr, esomeprazole 1–17 yr. [1][2]
PPIs provide superior symptom relief and healing of erosive esophagitis compared with H₂‑receptor antagonists (H₂RAs) in children. [3][4]
Omeprazole (0.7–3.3 mg/kg/day) improves GERD symptoms and normalizes esophageal pH monitoring in pediatric trials. [4][5]
Lansoprazole (0.7–3 mg/kg/day) has demonstrated complete healing of erosive esophagitis in children aged 1–12 years and is available in sprinkle‑capsule and flavored disintegrating tablet formulations. [4][5]6
Esomeprazole (0.7–3.3 mg/kg/day) can be administered by sprinkling capsule contents onto soft foods and is FDA‑approved for children 1–17 years old. 7

Ranitidine (5–10 mg/kg/day divided 2–3 doses) is approved for children 1 month–16 years, but its efficacy is limited by tachyphylaxis and inferior healing compared with PPIs. [2][3][4][6]
Famotidine (1 mg/kg/day divided twice daily) is approved for children 1–16 years, with the same limitations as other H₂RAs. [2][6]
Limitations of H₂RAs: tachyphylaxis develops within ~6 weeks, they are less effective than PPIs for symptom relief and erosive esophagitis healing, and their acid‑inhibiting effect lasts only about 6 hours. [3][4]

Initial PPI trial should last 2 weeks; if symptoms improve, continue therapy for a total of 8–12 weeks. 8
If no improvement after 2 weeks, reassess the diagnosis before escalating the dose or switching agents. 8

PPIs are generally well‑tolerated; up to 14 % of children may experience headaches, diarrhea, constipation, or nausea. [3][4]
Use of PPIs is associated with an increased risk of serious infections, including community‑acquired pneumonia, gastroenteritis, and candidemia. [3][4]
Long‑term PPI use (>2.5 years) can lead to enterochromaffin‑cell hyperplasia in up to 50 % of pediatric patients. [3][4]

Cimetidine should be avoided because it is linked to an increased risk of liver disease and gynecomastia in children. [3][4]
Routine use of prokinetic agents (e.g., metoclopramide, domperidone) is not recommended due to insufficient supporting evidence and the potential for serious adverse effects such as extrapyramidal reactions. [5][8]

Confirm a diagnosis of GERD (rather than physiologic reflux) using appropriate symptoms and/or diagnostic testing. 8
Begin with lifestyle modifications and non‑pharmacologic measures before initiating medication. 8
If medication is indicated, start a PPI at the recommended pediatric dose (e.g., lansoprazole 0.7–3 mg/kg/day, omeprazole 0.7–3.3 mg/kg/day, or esomeprazole 0.7–3.3 mg/kg/day). [6][1]
Re‑evaluate response after 2 weeks:
- Improved: continue the same PPI for a total of 8–12 weeks.
- Not improved: reassess the diagnosis before dose escalation or medication change. 8
After completing the treatment course, attempt discontinuation and monitor for relapse. 8
If relapse occurs, refer the child to a pediatric gastroenterology specialist. 8